Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLHEART-PRESERVED
NCT06081049Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Jun 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Colchicine with Placebo (2 arms). Primary endpoint: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 6 months. Started Jan 2024; status: recruiting.
02
Drugs
colchicine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06081049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081049.